<DOC>
	<DOCNO>NCT01058915</DOCNO>
	<brief_summary>In patient ST-segment elevation acute myocardial infarction ( STEMI ) increase LDL-cholesterol reduction ( rosuvastatin 40 mg ) provide incremental plaque stabilization ( change plaque composition ) plaque regression 12 month beyond benefit moderate LDL-cholesterol reduction ( rosuvastatin 5 mg ) ( assess IVUS VH ) .</brief_summary>
	<brief_title>Influence Intensive Lipid Lowering Treatment Compared Moderate Lipid Lowering Treatment Plaque Composition Patients With ST-Segment Elevation Myocardial Infarction ( MI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>ST segment elevation acute myocardial infarction 20 % &lt; angiographic diameter stenosis &lt; 50 % previously revascularized native coronary artery Statin na√Øve Pharmacologic lipid lower treatment index hospitalization Atrial fibrillation , well ratecontrolled Ventricle frequency variation factor 2 1 minute Unconscious patient Total cholesterol &gt; 7.0 mmol/l History statin induce myopathy , serious hypersensitivity reaction HMGCoA reductase inhibitor ( statin ) include rosuvastatin Pregnant woman , woman breast feeding , woman childbearing potential use chemical mechanical contraception positive serum pregnancy test ( serumhuman chorionic gonadotrophin [ BetaHCG ] analysis ) History malignancy ( unless document disease free period exceed 5years present ) exception basal cell squamous cell carcinoma skin , case study design investigate antineoplastic property rosuvastatin . Women history cervical dysplasia would permit enter study provide 3 consecutive clear Papanicolaou ( Pap ) smear Uncontrolled hypothyroidism ( TSH &gt; 1.5xULN ) Abnormal LFT 's History alcohol drug abuse within last 5 year ( may affect compliance ) Current active liver disease ( ALT/SGPT &gt; 2xULN severe hepatic impairment ( protect patient safety direct label currently approve statin ) Unexplained creatine kinase ( CK &gt; 3xULN ) ( To protect patient safety ) ( increase baseline acute ST segment elevation myocardial infarction day enrolment ) Serum creatinine &gt; 176mmol/L ( 2.0mg/dL ) ( unless protocol specifically aim investigate chronic renal disease population ) Participation another investigational drug study le 4 week enrolment study , accord subject local ethic committee requirement large period stipulate ( avoid potential misinterpretation overlap adverse event ) Treatments cyclosporine Treatment gemfibrozil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>ST-Segment Elevation Myocardial Infarction</keyword>
</DOC>